Deltec Asset Management buys $2,108,145 stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Deltec Asset Management scooped up 4,500 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 26, 2016. The investment management firm now holds a total of 19,500 shares of Celgene Corporation which is valued at $2,108,145.Celgene Corporation makes up approximately 0.51% of Deltec Asset Management’s portfolio.

Other Hedge Funds, Including , Skylands Capital boosted its stake in CELG in the latest quarter, The investment management firm added 11,075 additional shares and now holds a total of 39,475 shares of Celgene Corporation which is valued at $4,267,642. Celgene Corporation makes up approx 0.66% of Skylands Capital’s portfolio.Jolley Asset Management boosted its stake in CELG in the latest quarter, The investment management firm added 450 additional shares and now holds a total of 1,215 shares of Celgene Corporation which is valued at $130,637. Celgene Corporation makes up approx 0.10% of Jolley Asset Management’s portfolio.Rothschild Investment Corp Il boosted its stake in CELG in the latest quarter, The investment management firm added 285 additional shares and now holds a total of 87,598 shares of Celgene Corporation which is valued at $9,418,537. Celgene Corporation makes up approx 1.16% of Rothschild Investment Corp Il’s portfolio.Mai Capital Management reduced its stake in CELG by selling 1,560 shares or 29.42% in the most recent quarter. The Hedge Fund company now holds 3,743 shares of CELG which is valued at $384,406. Celgene Corporation makes up approx 0.03% of Mai Capital Management’s portfolio.

Celgene Corporation opened for trading at $110.66 and hit $112.43 on the upside on Friday, eventually ending the session at $112.19, with a gain of 0.84% or 0.93 points. The heightened volatility saw the trading volume jump to 54,86,248 shares. Company has a market cap of $86,903 M.

On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.Company shares were Reiterated by Sun Trust Rbsn Humphrey on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 147 from a previous price target of $145 .

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *